Description: GSK839 is a preclinical candidate for Tuberculosis treatment that was identified as result of a Wellcome Trust sponsored programme. GSK839 is a new chemical class that inhibits M. tuberculosis Tryptophan Synthase (TrpAB) in a selective manner. GLP tox studies are being planned for 2020.
Developer Associations: GlaxoSmithKline
Chemical Class: Tetrazole
Name of Target: Tryptophan Synthase (TrpAB)